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Abstract
Endometriosis is a complex, multifactorial, reproductive disorder present
in approximately 10-15% of adult women between the ages of 25-35. This
disorder occurs when endometrial glands and stroma grow ectopically on the
surface of the ovaries, pelvic peritoneum, fallopian tubes, and the uterus.
Endometriosis causes varying degrees of painful symptoms and infertility in
infected individuals. Three main theories of endometrial accumulation attempt
to explain the etiology of this elusive disease. There have been various
approaches to staging of endometriosis symptoms that attempt to standardize
classification as well as predict pain and infertility. Angiogenesis, necessary to
the survival of endometrial tissue, along with immune dysfunction and evasion
have been examined as possible contributing factors to the development of
endometriosis. Certain angiogenic factors are upregulated in ectopic endometrial
tissue and endometriotic lesions, while decreased cytotoxicity of T cells is shown
to be an abnormal immune process observed in individuals with this disorder.
Other factors including exposure to environmental toxicants, diet, and
population specific polymorphisms have also been examined for their role in this
disease. While various genetic variations have been identified as increased risk
factors for endometriosis in certain populations, there has not been a specific
genotype that demonstrates increased risk for this disease in all populations.
Endometriosis-induced animal models, which include rodents and non-human

	
  

	
   iv	
  

primates, are primarily responsible for the advancement of our understanding of
this disease. Although limitations exist for animal models, they have been an
important contributor to current research. There is no cure for endometriosis, but
various treatment options exist for both pain and infertility. The purpose of this
thesis is to review current literature relevant to the etiology, development, and
treatment of endometriosis.
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Chapter I: Introduction
Endometriosis is a female reproductive disorder present in approximately
15% of adult women between the ages of 25-35 (Macer 2012). This disorder
occurs when the endometrial tissue (cells that line the uterus) grows in other
areas of the body. This abnormal growth of endometrial tissue, is referred to as
ectopic endometrium and can occur anywhere in the body, but is most
commonly observed in the pelvis—on the outer surface of the ovaries, fallopian
tubes, or the uterus.
The cyclic shedding of ectopic endometrium within the abdomen can
cause irritation; lower back, intestinal, or pelvic pain, heavy menstrual periods or
spotting between periods, dysmenorrhea, dyspareunia, and infertility (Constanti
1998). The etiology of endometriosis is unknown, however, there are three major
theories that attempt to explain the origin of this disease. The most commonly
accepted theory is that of retrograde menstruation proposed by John A.
Sampson, M.D. in 1927 described below (Alford 2010). Meyer’s theory promotes
the idea of coelomic metaplasia and Halban’s theory focuses on endometrial
spreading via the vasculature and lymphatics.
Endometriosis is an estrogen dependent disease. When estrogen levels
increase during the menstrual cycle the ectopic tissue grows and then regresses
in the absence of estrogen similar to the activity of normal uterine endometrium
(Constanti 1998). Current research suggests that genetic variation and
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polymorphisms contribute to the disease within certain populations. A few
animal models have been developed to study endometriosis using mice, rats, and
nonhuman primates. While differences between the rodents’ estrous cycle and a
woman’s menstrual cycle prevent a direct comparison of disease findings, there
is still much to learn about disease etiology using these models. A specific
species of baboon has also been developed to simulate endometriosis and has a
similar menstrual cycle to that of a human, but it is difficult to perform extensive
experimental manipulations in this model due to the high cost associated with
utilizing these animals. There are specific advantages and disadvantages to the
study of each endometriosis animal model which will be discussed below.
Current research also explores other factors potentially influencing the
development of endometriosis. These factors include angiogenesis and immune
response. Angiogenesis is the formation and growth of new blood vessels. This is
required for the development and survival of endometrial tissue; without a
blood supply there would be no oxygen or nourishment necessary for
maintaining this tissue. Studies have explored the role of angiogenic factors in
endometriosis development.
Another such factor includes dysfunction of the immunological response
to the misplaced endometrium. The dysfunction of necessary immune cells
normally recruited to the uterine lumen during the menstrual cycle could play a
role in the ability of ectopic endometrial tissue to implant and proliferate.
Immune cells such as macrophages and lymphocytes required to clear the
normal shedded endometrium could lead to pathology if unable to perform their
normal function. Also, environmental factors, such as exposure to environmental
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toxicants and chemical pollutants, and certain foods such as fatty acids have been
studied for their potential role in the development of this disease.
While there is no cure for endometriosis there are treatments that help
reduce the symptoms (Senapati 2011). This review will discuss the current
research and literature as it pertains to the possible origins, development, genetic
variation, pathology, and treatment of endometriosis.
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Chapter II: The Menstrual Cycle
2.1 Overview
Endometriosis is defined as glandular and stromal tissue of the
endometrium outside of the uterus (Burney 2012). Ectopic endometrium, similar
to eutopic endometrium, proliferates and sheds in response to hormonal
fluctuations. These fluctuations are due to physiological changes in the ovary
and the regulation of these changes by the hypothalamic-pituitary axis. The
normal changes that characterize the phases of the menstrual cycle are
responsible for variations in the histology of the reproductive tract, including the
endometrium, the understanding of which will provide the basis of
endometriosis pathogenesis. The changes that occur during the menstrual cycle
in response to hormonal regulation, changes in the histology of the reproductive
tract, and functional and mechanistic differences between eutopic and ectopic
endometrium will be reviewed in this chapter.
2.2 Phases of the Menstrual Cycle
Menarche, the initiation of menses and fertility, occurs in young women
between the ages of 9-14 (Ross 2011). During this time there are changes that
occur to a woman’s reproductive organs. The ovaries produce the steroid
hormones, progesterone and estrogen, which along with neural activity regulate
these changes. The ovarian cycle in women consists of two phases: an estrogen
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dependent follicular phase and a progesterone dependent luteal phase. Due to
the variation in hormones that are produced during the menstrual cycle, changes
occur within the uterus that promote an environment for embryo implantation.
The hypothalamic-hypophyseal portal system is ultimately responsible for
regulating the changes in plasma hormone concentration (Constanti 1998). The
hypothalamic-hypophyseal portal system moves blood between a primary
capillary bed in the median eminence and a second capillary bed in the anterior
pituitary. When hypothalamic peptide hormones are released into the portal
system they are transported by the portal veins directly to the anterior lobe.
Through the actions of Gonadotropin-releasing hormone (GnRH), the
hypothalamus controls secretion of the gonadotrophins, follicle stimulating
hormone (FSH) and luteinizing hormone (LH), from the anterior pituitary gland
(Constanti 1998). GnRH is released in a pulsatile fashion from the hypothalamus
into the portal system and travels to the anterior pituitary, where it acts on its
receptors to cause release of the gonadotropin hormones. During the follicular
phase of the menstrual cycle the plasma levels of FSH and LH slowly rise; this
causes the ovarian follicles to mature. As estrogen levels increase in circulation, it
negatively feeds back on both the anterior pituitary gland and the hypothalamus,
this decreases the amount of estrogen produced by the ovarian follicular somatic
cells.
The initial rise in estrogen characterizes the follicular phase occurring the
first 14 days of the menstrual cycle (Ross 2011). This phase is also referred to as
the proliferative phase, because there is proliferation of granulosa and theca cells
of the ovarian follicle and of the endometrium. Both FSH and estrogen also
increase the sensitivity of granulosa cells for FSH by increasing the number of
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surface receptors for this hormone. By the late follicular phase there is a switch as
high estrogen begins to work in a positive feedback mechanism at the level of the
anterior pituitary and hypothalamus. This positive feedback mechanism is
responsible for the LH surge and increased levels of progesterone that occur
during the luteal phase. Increased estrogen levels are due to a proliferation of
estrogen secreting follicular cells and through estrogen action on both the
hypothalamus and anterior pituitary. High estrogen levels due to positive
feedback and the surge of LH and FSH cause release of the secondary oocyte and
surrounding cells from the ovary.
The luteal phase, days 15-28 of the menstrual cycle, is dependent on high
progesterone levels (Ross 2011). Progesterone is produced by the residual
follicular cells, which form the corpus luteum. The progesterone prepares the
endometrium for implantation by causing the endometrium to thicken,
vascularization to increase, and proliferation to decrease. If the secondary oocyte
is not fertilized in the fallopian tubes, it passes through to the uterus. In the
absence of fertilization and implantation into the uterine wall, the corpus luteum
regresses, resulting in a decline in estrogen and progesterone levels. Without the
sex hormones to maintain the endometrium degradation occurs (Gray 2005). The
shedding of the endometrium with the exception of the basal layer typically lasts
about four days and its onset starts the next cycle.
2.3 Role of Estrogen in the Menstrual Cycle
The steroid hormones, estrogen and progesterone, are produced in the
ovaries by a process called steroiodogenesis (Ross 2011). These hormones,
formed from a cholesterol precursor, are synthesized in a cyclic manner and are
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responsible for the changes that occur in the female reproductive system.
Estrogens are critical regulators of normal reproductive function (Heldring 2007).
Three forms of estrogen exist as shown in Figure 2.1: 17β-estradiol (E2), estriol
(E3), and estrone (E1). E2 is the predominant and most potent form of estrogen in
adult pre-menopausal women. E3 increases during pregnancy and E1 is the
major form of estrogen in post-menopausal women.
Estrogen is important in the development of both internal and external sex
organs and is also responsible for the female sex characteristics that develop in
young women at puberty. Two types of estrogen receptors exist in the body and
establish the physiological functions of estrogen, estrogen receptor alpha (ERα)
and estrogen receptor beta (ERβ) (Burns 2012). Both receptors are part of the
nuclear receptor family of transcription factors and are vital to the function of the
reproductive tract, breast, bone, and brain (Heldring 2007). Accepted research
shows marked functional differences between these two receptors, including the
opposite effects these receptors induce on promoters of genes involved in
proliferation. Estrogen bound to ERα has been shown to induce the transcription
of pro-proliferative target genes, such as cyclin A and c-Myc mRNA (Zhang
2009), whereas ERβ is responsible for activating anti-proliferative target genes
and producing anti-inflammatory effects (Heldring 2007).
As previously mentioned, LH is released from the anterior pituitary and
stimulates theca cells to produce testosterone. Under the actions of LH, the lipidsoluble molecule cholesterol is converted to pregnenolone by the cytochrome
P450 cholesterol side-chain cleavage enzyme complex in theca cells (Constanti
1998). Through a series of reactions pregnenolone is converted into testosterone,
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which traverses the theca cell and basement membrane and diffuses into
granulosa cells. FSH binding to its receptor on granulosa cells increases
aromatase enzyme synthesis and activity, which is responsible for converting
testosterone into estradiol.
Progesterone, secreted by the corpus luteum during the luteal phase of
menses, enables the uterus to adapt for pregnancy by allowing for changes in the
endometrium (Ross 2011). The rise and fall of estrogen and progesterone
characterize the menstrual cycle. During the menstrual phase of the uterine cycle,
regression of the corpus luteum occurs, and decreases in estradiol and
progesterone allow for the endometrial lining to shed. This cyclic sloughing and
regenerating feature distinguishes endometrial tissue and thus endometriosis
from other pathology such as cancerous growths.
2.4 Histology of the Female Reproductive System and Endometrium
The female reproductive tract is composed of a pair of almond-shaped
ovaries and fallopian tubes that come together at the uterus (Ross 2011). The
primary functions of the ovaries are oogenesis and steroidogenesis. A center
medullary region and an outer cortex form the bulk of the ovarian structure,
while the surface is covered in a layer of simple cuboidal cells, referred to as the
germinal epithelium. The medulla contains loose connective tissue, blood
vessels, and lymphatics; while the cortex surrounding the medulla contains the
follicles surrounded by smooth muscle fibers. The female germ cells, oogonia,
undergo mitosis and stop in prophase I of meiosis before they become
primordial follicles (Blake 2012). This occurs in the fetus. The long period of
meiotic arrest leaves the primary oocyte vulnerable to potentially harmful
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environmental influences that could develop years after birth. Simple squamous
follicular cells surround the primary oocyte forming the primordial follicle.
At the start of the menstrual cycle, due to increasing levels of FSH, a
group of primordial follicles enlarge and become primary follicles (Constanti
1998). The primary and antral stages of development are referred to as the
growing follicle (Blake 2012). The process of developing an ovulatory follicle
from this early stage takes 3-4 menstrual cycles. The transition between
primordial follicle and primary follicle involves morphological changes; the
oocyte begins to enlarge and the surrounding squamous cells become cuboidal
(Ross 2011). The change from squamous to cuboidal of the surrounding follicular
cells characterizes a primary follicle. The growing oocyte emits a gel-like,
nutritive protein material called the zona pellucida, which separates it from the
follicular somatic cells. The single layer of follicular cells undergoes rapid
proliferation and forms the granulosa cell layer. The stromal cells surrounding
the follicle form a sheath of connective tissue called the theca folliculi made up of
a theca interna and theca externa. The theca interna is highly vascularized and
contains LH receptors, while the theca externa contains smooth muscle.
As the primary follicle continues to grow into the antral follicle the
granulosa cell proliferates and becomes 6-12 cell layers thick (Ross 2011). The
granulosa cells that are associated with the oocyte are referred to as the cumulus
oophorus and the antrum is formed from the combined fluid-filled cavities
between granulosa cells. Through a process not completely understood one
follicle continues to grow and becomes the dominant or Graafian follicle
extending throughout the entire cortex of the ovary and causing a bulge. The
other follicles at different stages regress and are reabsorbed through atresia.
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The LH surge causes ovulation in which the secondary oocyte and
surrounding cells are released from the Graafian follicle (Ross 2011). The cells of
the cumulus oophorus immediately surrounding the oocyte and remain with it at
ovulation are called the corona radiata. The secondary oocyte and the corona
radiata exit the ovary through a break in the germinal epithelial layer and move
into the fallopian tubes. The secondary oocyte is a product of the first meiotic
division. The daughter cells of the primary oocyte each receive the same amount
of chromatin, however, one daughter cell receives a majority of the cytoplasm
and becomes the secondary oocyte. The second daughter cell with a lesser
amount of cytoplasm becomes the first polar body. After ovulation the secondary
oocyte is only viable for about 24 hours, if fertilization fails to occur, the
secondary oocyte degenerates.
The wall of the fallopian tubes, also called uterine tubes or oviducts, are
made up of three layers (Ross 2011). The outer most layer is the serosa or
peritoneum, the middle layer the muscularis, and the innermost layer the
mucosa. The mucosal lining of the uterine tubes contains both ciliated and nonciliated simple columnar epithelium. The cilia, composed of an internal core of
microtubules, are apical modifications that exist on the surface of epithelial cells.
These microscopic structures beat together in order to aid in moving the
secondary oocyte or embryo (if fertilized) from the oviducts into the uterus. The
randomly dispersed non-ciliated peg cells provide nourishment for the embryo.
The uterus is a muscular organ about 7 cm long, 4 cm wide, and 2.5 cm
thick (Ross 2011). It is divided into three regions: the body, the fundus, and the
cervix. The uterine wall of the body and the fundus is composed of the
endometrium and myometrium. The myometrium is the smooth muscle layer of
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the uterus that has the ability to contract in response to stimulation (Blake 2012).
Oxytocin stimulates uterine contraction at the end of pregnancy by acting on its
receptor and through initiation of prostaglandin synthesis. Oxytocin has an
increased effect due to estrogen, which sensitizes the myometrium to oxytocin by
up-regulating its receptor. Progesterone has the opposite affect and causes
suppression of uterine contractions.
The mucosal lining of the uterus is called the endometrium, which can be
divided into the stratum basale and the stratum functionalis (Ross 2011). The
stratum basale, or the basilar zone, gives rise to the stratum functionalis that
grows and is then shed each month. The monthly changes that occur in the
endometrium correspond to the hormonal changes of the follicular and luteal
phases of the ovarian cycle (Gray 2005).
The endometrial tissue that lines the uterine cavity is made up of simple
columnar epithelium (Young 2000). The supporting stroma contains simple
tubular glands. The endometrium is 1-2 mm thick at the beginning of a cycle and
the glands are straight, non-secreting, and lined with columnar epithelium (Gray
2005). Early in the proliferative phase, re-epithelialization or resurfacing occurs,
in which the remnant basilar zone of the uterine glands proliferate and migrate
to cover the endometrial surface stripped from its mucosa by menstrual
shedding. This process concludes about 5-6 days after the start of shedding.
As ovarian produced estrogen levels rise throughout the proliferative
phase the endometrial cells begin to rapidly divide (Young 2000). Estradiol acts
through receptors located on stromal and epithelial cells, which also causes the
simple tubular glands to proliferate, forming numerous glands. The proliferative
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phase is maintained until ovulation by the increasing synthesis and secretion of
estrogen from the developing ovarian follicles.
The secretory phase of the uterine cycle occurs after ovulation and is
characterized by progesterone and estrogen induced endometrial changes (Gray
2005). Estrogen causes progesterone receptor expression and is therefore an
important regulator of progestational effects (Blake 2012). Progesterone’s effects
on endometrial stromal cells, also referred to as the decidual reaction, are evident
in the early secretory phase. During this phase the endometrium grows up to 6
mm and the glands become highly coiled (Young 2000). Endometrial stromal
glands are induced by progesterone to produce a thick, glycogen-rich secretion,
which is an important nutritive factor for the embryo while vascular connections
are being established with the mother’s vasculature. In the absence of
fertilization, the late secretory phase of the menstrual cycle shows a regression of
glandular secretory activity.
In the absence of fertilization the menstrual phase of the uterine cycle
begins (Young 2000). As previously mentioned, without progesterone, the
endometrium can no longer be maintained and is shed during menstruation.
Blood and necrotic endometrium appear in the uterine lumen, to be discharged
from the uterus and out through the vagina as menstruation (Gray 2005). During
this time FSH secretion is induced, causing a new cycle of follicle development
and production of estrogen, which begins the process of resurfacing. Although
the process of menstruation represents the end-point of the cycle of endometrial
changes, the first day of menstruation also marks the beginning of a new
proliferative phase.
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The uterine blood supply spans from the myometrium through both
layers of the endometrium and is predominantly arterial (Ross 2011). The
distinguishing arrangement of the endometrium’s arterial supply has essential
influences on the menstrual cycle (Young 2000). Branches of the uterine artery
extend through the myometrium and bifurcate into two different types of
arteries, spiral arteries and straight arteries, as they extend into the endometrial
layer.
The straight arteries are short and supply the stratum basalis of the
endometrium (Young 2000). Spiral arteries are opposite; they are long, coiled and
thick-walled. These arteries supply the surface of the endometrium giving off
numerous branches that surround the stromal glands. The spiral arteries, unlike
straight arteries, react to hormonal changes of the uterine cycle. The end of the
secretory phase, characterized by inhibition of estrogen and progesterone
secretion, causes the spiral arteries to constrict and leads to an ischemic phase.
This phase immediately precedes menstruation and induces degeneration of the
endometrium. The spiral artery along with lacunae and capillary beds are part of
the stratum functionalis, which is shed and then reformed each month (Ross
2011).
2.5 Ectopic Endometrium
Eutopic endometrium is thought to be the tissue from which
endometriosis develops. Because of this, a comparison between ectopic and
eutopic endometrial tissue is important to the study of this disease. Ectopic
endometrium, no matter the location, typically resembles the eutopic
endometrial characteristics of proliferation and shedding. For this reason the
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hormonal responses of both tissue types is presumed to be similar. However,
studies have shown this is not the case and that other factors are involved with
the development and regulation of ectopic endometrial lesions (Metzger 1993).
Jones et al (2009) examined the ultrastructure of ectopic peritoneal lesions
using electron microscopy and immunohistochemistry. Heterogeneity was
observed among the structure of endometriotic lesions suggesting nonuniformity, dissimilar to eutopic endometrium. A mix of all three cell types
(squamous, cuboidal, and columnar) were observed in the excised peritoneal
lesions. The most similar structural observation was seen in a biopsy taken on
day 9 of this study, showing columnar glandular tissue, euchromatic nuclei, and
a normal distribution of organelles. Certain homogenous features were noted in
this study including a significant lack of glycogen accumulation normally seen in
the second part of the menstrual cycle.
As previously mentioned, glycogen is the main product of endometrial
glands, and is important in nourishing an embryo after implantation into the
uterine wall. The lack of glycogen observed in these ectopic lesions may be
associated with the increased estrogen levels found in endometriotic lesions
(Bulun 2000).
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Figure 2.1 Estrogen Metabolites (From Hammond CR, Soules M: Clinical
significance of estrogen metabolism and physiology. Contemp OB/GYN 11:41,
1978). Copyright © 2004 - 2011 Lippincott Williams & Wilkins, Two Commerce
Square, 2001 Market Street, Philadelphia, PA 19103 U.S.A. All rights reserved.
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Chapter III: Theories of Endometrial Accumulation
3.1 Overview of Endometriosis Theories
Three main theories of endometriosis etiology exist today. All three have
received varying amounts of support (Vinatier 2001), however, the most
accepted theory of endometriosis pathogenesis is Sampson’s theory of retrograde
menstruation. Because retrograde menstruation occurs in a larger percentage of
menstruating women than those diagnosed with endometriosis, other factors
must be involved in the pathogenesis. This theory is the basis for a lot of current
research that seeks to find potential immunologic, angiogenic, and
environmental factors that may allow for the implantation and development of
misplaced endometrial tissue.
The other widely known theories of endometriosis etiology include,
Meyer’s theory of coelomic metaplasia and Halban’s theory of lymphatics and
vascular metastasis, which were developed around the same time (Hoffman
2011). The theory of coelomic metaplasia is based on the potential morphological
changes of cells found in the ovary; because cells that make up both the ovary
and the uterus are derived from the same precursor cell, the potential for
metaplasia exists. Halban’s theory of lymphatics and vascular metastasis
suggests that endometrial tissue is taken up through the lymphatic spaces and
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the vasculature, causing distant lesion formation. These theories along with
related literature will be reviewed here.
3.2 Sampson’s Theory of Retrograde Menstruation
In 1927 John A. Sampson, M.D. published a paper entitled “Metastatic or
Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial
Tissue into the Venous Circulation” (Sampson 1927). This paper discussed this
theory of endometriosis etiology based on retrograde menstruation and
implantation. Sampson’s theory was formed from his own observations during a
series of hysterectomies performed during various stages of the menstrual cycle.
Sampson’s primary theory suggests that the pathology of endometriosis
occurs when endometrial tissue is shed from the mucosa of the uterus and flows
back into the oviducts and into the peritoneum (Sampson 1927). Endometriosis
can be induced in the baboon by endocervical canal resection, which prevents
endometrial tissue from being discharged from the uterus and out through the
vagina; this simulates retrograde menstruation (Dehoux 2011). This induced nonhuman primate model for endometriosis, discussed in greater detail in Chapter
9, supports this theory.
Sampson also suggested that endometrial tissue maybe taken into venous
circulation of the uterus during menstruation, which would account for the
etiology of endometrial tissue growing away from the uterus, such as on the
vagina, groin, and rectum (Sampson 1927).
While retrograde menstruation has been shown to occur in up to 90% of
women (Bokor 2009 and Burney 2012) with viable endometrial cells found in the
fallopian tubes and in the peritoneum (Halme 1984), it would be expected to
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display a higher incidence of endometriosis. This indicates that other factors
besides endometrial tissue found outside of the uterine mucosa are necessary for
the formation of this disease (Alford 2010).
3.3 Meyer’s Theory of Coelomic Metaplasia
Meyer’s theory, also commonly referred to as the theory of coelomic
metaplasia, explains only ovarian and pelvic peritoneal endometriosis (Meyer
1919). This theory is established on the basis that both the germinal epithelium of
the ovary, the pelvic peritoneum, and that of the uterus are derived from the
same precursor cell. It infers that the germinal epithelium of the ovary and the
pelvis can morph by metaplasia into endometrial tissue (Vinatier 2001). This
theory is appealing due to its suggestion of the etiology of endometriosis without
menstruation playing a factor. However, there are also several facts unexplained
by this theory.
First, if peritoneal metaplasia explains the origin of this disease, a similar
disease should be observed in males (Vinatier 2001). Coelomic mesothelium, also
mesodermal epithelium, is one of three common cell sources of testes and
ovarian development (Ross 2011). In males, coelomic mesothelium gives rise to
Sertoli cells and the primary sex cords. As development continues, the primary
sex cords differentiate into the seminiferous cords, which later develop into the
seminiferous tubules, straight tubules, and rete testis. If metaplasia occurs with
these precursor cells in women, it would be most likely, also be seen in men.
Secondly, coelomic metaplasia would be observed in all tissues derived
from the coelomic epithelium, which include both striated and smooth muscle,
the heart, blood and lymphatic vessels, the spleen, kidneys, and the adrenal
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cortex (Ross 2011). Finally, if coleomic metaplasia mimics typical metaplasia,
then endometriosis should be more common in older women.
While this theory makes sense, because cells of the ovary, pelvic
peritoneum, and endometrial cells are both derived from the same coelomic
precursor cell in the developing embryo, it has been difficult to provide scientific
evidence to support it (Alford 2010). However, studies that examine benign and
malignant epithelial ovarian tumors and the correlation between endometriosis
may provide support for this theory. Epithelial ovarian tumors are considered to
be derivatives of germinal epithelium; the presence of ovarian surface epithelium
could be accounted for by coelomic metaplasia (Somigliana 2006).
3.4 Halban’s Theory of Lymphatic and Vascular Metastasis
Another theory of endometriosis etiology is that of vascular and
lymphatic metastasis (Vinatier 2001). Halban suggested that during the invasion
of the myometrium by its mucosa, bits of the endometrial tissue are taken up into
lymphatic spaces between muscle bundles of the uterine wall and are
transported to superficial lymphatics. This theory suggests that distant lesions
are formed by endometrial tissue being taken up by the blood supply and
lymphatic vessels in the uterus and transported to other areas of the body. While
this theory could potentially explain distant lesions, it does not explain the
particular location of most endometrial lesions, which is on the surface of ovaries
or within the abdominal peritoneum.
3.5 Conclusions
These theories of endometriosis etiology have provided researchers with a
starting point, leading to some important discoveries about factors involved in
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the development of this disease. However, these theories have been difficult to
support and therefore remain inconclusive.
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Chapter IV: Diagnosing Endometriosis
4.1 Overview
The primary method of diagnosing endometriosis today is via
laparoscopy, which sometimes includes taking a biopsy for a histological
diagnosis (Hoffman 2011). Due to the varying degrees of endometriosis among
women there have been attempts to create a standardized classification system in
order to objectively evaluate the extent of the disease based on the amount of
ectopic endometrial tissue and the appearance of the endometriotic lesions.
The first classification system, provided by the American Fertility Society
(AFS) in 1979, was a scoring system that experimented with labeling the severity
of the disease based solely on observation (Adamson 2011). Since then there have
been two revisions of this classification systems as well as other methods of
classification. These include the ENZIAN classification system and the
Endometriosis Fertility Index (EFI), which will be discussed in this chapter.
4.2 The American Fertility Society Classification System
The AFS, later renamed the American Society for Reproductive Medicine
(ASRM), revised its classification system in 1985 and is currently the best known
and most widely used classification system for endometriosis (Haas 2013). The
revision distinguishes between superficial and invasive levels of the disease.
According to the revised classification system, there are four stages
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of endometriosis: stage I (minimal), stage II (mild), stage III (moderate), and
stage IV (severe). Staging is determined by five factors, including the location of
the endometrial lesions, the size of the lesions, the presence of adhesions, the
extent of the adhesions, and the degree of obliteration of the posterior cul-de-sac
(Adamson 2010). Similar results were published in support of the AFS’s revised
classification of endometriosis and concluded that visual documentation of
endometriotic lesions were reproducible and therefore sufficient in making a
determination on the stage of endometriosis according to the American Fertility
Society classification (Rock 1995).
The ASRM produced a second revision of the classification system for
endometriosis in 1997 in order to update the system based on surgical findings
(rASRM classification system). There were no apparent changes made to the
stages defined in the 1985 classification, however, an additional description of
lesion morphology (white, red, and black) was included in this revision. While
the second rASRM’s scoring system is the most commonly used system to
determine the level of severity of endometriosis, studies have shown that this
classification does not predict fertility or the severity of associated pain in
individuals (Guzick 1997). This classification system also lacks assessment of
deep infiltrating endometriosis. A work sheet for this classification system is
shown in figure 4.1 However, both the ENZIAN system and the EFI have set out
to accomplish this by making other scoring systems that measure pregnancy
rates for endometriosis patients as well as developing methods in predicting
pain. These scoring systems are discussed in the following sections.
In order to determine the rASRM score, numbers are given to
endometriotic lesions found in the peritoneum and ovaries using points that are
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to represent these lesions (Haas 2013). In addition, points are given for adhesions
on the ovaries and the oviducts as well as for partial or complete posterior culde-sac obliteration. Each stage is scored as follows: stage I (1-5 points), stage II (615 points), stage III (16-40 points), and stage IV (>40 points).
4.3 The ENZIAN Classification System
Deep infiltrating endometriosis (DIE) is a special type of endometriosis
that infiltrates the peritoneal surface >5 mm (Koninckx 1994). These lesions are
extremely active and significantly correlated with pelvic pain (Koninckx 1991).
The ENZIAN classification system was developed because the rASRM
classification of endometriosis does not assess this particular development of
endometriosis.
The ENZIAN classification system was established in 2005 with the
intentions of supplementing the rASRM’s classification of endometriosis rather
than challenging it. The ENZIAN classification system attempts to provide a way
to classify DIE. In February 2011 the second revision of the ENZIAN
classification system was released. The revised classification system divides the
retroperitoneal structures into three separate compartments as follows:
Compartment A (retrovaginal septum and vagina), Compartment B (sacrouterine
ligament to pelvic wall), and Compartment C (rectum and sigmoid colon) (Haas
2012). Similar to the rASRM system, the severity rating for each compartment is
indicated by a grading scale. The grading system is 1-3 based on the depth of
invasion: a grade of 1 will be used to indicate invasion <1 cm, grade 2 indicates
invasion 1-3 cm, and grade 3 indicates invasion >3 cm. While the ENZIAN
system of classification is meant to supplement the rASRM classification of
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endometriosis, it is not yet internationally accepted. A worksheet for the
ENZIAN classification system is shown in figure 4.2.
4.4 The Endometriosis Fertility Index
As previously mentioned, classification of endometriosis based on the
rASRM classification system is unable to predict fertility in women suffering
from endometriosis. The EFI staging system was created in order to effectively
assess fertility outcomes based on clinical data (Adamson 2010). This clinical tool
has been deemed clinically useful for patients surgically diagnosed with
endometriosis attempting non-IVF conception. A study was performed using
data collection and statistical analysis on 579 infertile patients in order to
produce this method of staging. After creation of this fertility index, data was
then collected and EFI scores were calculated on an additional 222 patients.
Subsequently, the actual pregnancy rates compared with the EFI predicted rates.
The EFI score is a sum total of two separate scores: a historical factors
score and a least function (LF) score. The historical components evaluated in
preliminary analyses were age, duration of infertility, and pregnancy history
(Adamson 1993). These determinants were also used to make up the historical
factors score, while the LF score based on surgical observations was used to
supplement this (Adamson 2010). The LF score is determined by the observation
of dysfunction of the reproductive structures involved in reproductive processes
including, the fallopian tubes, fimbria, and ovaries. The points used to calculate
LF scores are 0= absent or nonfunctional, 1= severe, 2= moderate, 3= mild
dysfunction, or 4= normal; these points are given by a surgeon with respect to
the capability of the organ/structure to function. Scores for each structure
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(fallopian tubes, fimbria, and ovaries) were given separately for each side and
then combined. After all scores were given, they are summed for both the right
and left side of each structure. The lowest, corresponding to the severity for the
right and left of each side, are combined for the LF score. The final EFI score is
then calculated by adding the historical factors score and the LF score together.
The EFI surgery form is shown in figure 4.3.
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Figure 4.1 "Revised American Fertility Society Classification of Endometriosis:
1985." Revised American Fertility Society Classification of Endometriosis: 1985.
Fertil Steril 43 (3): 351-2.
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Figure 4.2 The revised ENZIAN classification of endometriosis. Reprinted from
Acta Obstetricia et Gynecologica Scandinavica, Dietmar Haas, Omar Shebl,
Andreas Shamiyeh, Peter Oppelt, “The rASRM and the Enzian classification for
endometriosis: their strengths and weaknesses,” 3-7, © 2012 The Authors © 2012
Nordic Federation of Societies of Obstetrics and Gynecology, with permission
from John Wiley and Sons

27	
  

Figure 4.3 The EFI Surgery Form. Reprinted from Fertility and Sterility, Volume
94, G. David Adamson and David J. Pasta, “Endometriosis fertility index: the
new, validated endometriosis staging system,” 1609-1615, © 2010, with
permission from Elsevier.
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Chapter V: Angiogenesis
5.1 Overview
Angiogenesis, the formation of new blood vessels from preexisting
vessels, is crucial to the development, implantation, and progression of
endometriosis. In normal women, endometrial stromal cells release angiogenic
factors, which signal the vasculature of the stratum functionalis to proliferate.
Vascular endothelial growth factor (VEGF) is the most studied pro-angiogenic
factor that signals angiogenesis and vascularization (Hoffman 2011). Endothelial
cells are steadily experiencing shear stress or the pressure applied by blood flow.
Shear stress, inflammation, and hypoxia, or oxygen deficiency, in cells induces
VEGF production (Ross 2011). The role of VEGF and other angiogenic factors are
among current research topics in endometriosis pathology.
Ectopic endometrial tissue requires angiogenesis for development, which
suggests its potential role in endometriosis pathology. The complex process of
angiogenesis begins with degradation of the basement membrane of a capillary
or vein, migration and proliferation of endothelial cells, sprouting and adjoining
of two vessels, and finally maturation of those vessels. In addition to VEGF,
Fibroblast Growth Factors (FGFs), Platelet-derived Growth Factor (PDGF),
Transforming Growth Factor-alpha (TGFα), Transforming Growth Factor-beta
(TGFβ), and Tumor Necrosis Factor-alpha (TNFα) are the most significant
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inducers of angiogenesis as it relates to the female reproductive system. The role
of VEGF, FGF, and PDGF in the normal female reproductive tract and in
endometriosis will be presented below.
5.2 VEGF, FGF, and PDGF in the normal female reproductive tract
VEGF is a secreted heparin-binding, dimeric glycoprotein that acts as a
chemo-attractant to endothelial cells. It is crucial to blood vessel formation, as
studies have shown that inactivation of VEGF in embryonic stem cells leads to
malformation of blood vessels within the embryo (Ferrara 1996). VEGF has
several isoforms encoded by a single gene (Enholm 1997). These isoforms, VEGFA, VEGF-B, and VEGF-C, are created through alternative splicing methods and
have different effects on various populations of endothelial cells (Abulafia 1999).
Tumors produce elevated levels of VEGF in order to establish a vascular supply
(Shweiki 1993); it is believed that ectopic endometrial tissue utilizes a similar
action for survival.
VEGF-A is the most important angiogenic factor of the various isoforms
and is typically studied for its role in tumor growth (Ferrara 2009). It is
responsible for inducing both normal and pathologic angiogenesis and it is
believed to play a central role in the growth and maintenance of endometriosis
(Ferrara 2009 and Donnez 1998). VEGF-C was determined to be the ligand for
the VEGF receptor expressed predominantly on venous endothelium of early
embryos and lymphatic endothelium of adult tissues (Enholm 1997). This
isoform of VEGF is increased in endometrium and promotes endothelial
functions and vascular permeability (Xu 2013). VEGF-B, like VEGF-A and VEGF-
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C, is expressed in most tissues, but its greatest concentrations are in the heart and
skeletal muscle (Enholm 1997), which explains its lower effects on endometrium.
During the normal menstrual cycle the angiogenic response is structured
and controlled with rapid growth of vessels during the secretory phase and
arrested growth shortly after (Abulafia 1999). Changes in endometrial VEGF
mRNA expression are observed during the menstrual cycle. Its expression
increased three to five times from the early proliferative phase to the late
secretory phase where it was maximal (Shifren 1996). VEGF mRNA was present
in uterine glandular epithelial cells and stromal cells. The increase in VEGF
mRNA expression by the late secretory phase suggests that vascular endothelial
growth factor may impact expansion and coiling of the spiral arteries. VEGF
mRNA expression is observed in many different cell types of the female
reproductive system that are either involved in the process of steroidogenesis, for
example, granulosa, theca, and luteal cells; or are steroid responsive, including
oviductal epithelium and endometrial stromal cells. VEGF expression is
hormonally regulated and up-regulated in cells that produce steroid hormones
(Shweiki 1993). Overexpression of VEGF leads to pathology, including cancers
and endometriosis, which similarly require a blood supply for cell survival.
Fibroblast growth factors (FGFs) are secreted proteins produced by
vascular endothelial and smooth muscle cells. FGFs and their receptors are
regulators of angiogenesis, steroidogenesis, proliferation, differentiation,
migration, and cell-survival (Brooks 2012). FGFs are heparin-binding growth
factors, while their receptors are part of the tyrosine kinase receptor family
(Chaves 2012). After various studies identified expression of FGFs in
reproductive tissue, further experimentation demonstrated the involvement of
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FGFs in the physiological regulation of reproductive processes and ovarian
function.
FGF-2 is the most studied and characterized growth factor of the FGF
family and is involved in the survival of reproductive cells. Similar to VEGF,
FGF-2 is an angiogenic growth factor present in both normal and abnormal
endometrium. This factor is important not only for angiogenesis in general, but
also specifically for angiogenesis of endometrial tissue (Möller 2001). A study by
Zhou et al (2005) demonstrated that FGF-2 could maintain oocyte survival in
culture, but did not seem to have an effect on growth. A second study also
demonstrated that FGF-2 prevents granulosa cell apoptosis in an in vitro study
with rat granulosa cells (Tilly 1992). Dysregulation of the FGF/FGFR pathway
and overexpression of FGFR have been correlated with developmental disorders,
cancers, and endometriosis.
Another factor involved in angiogenesis and therefore studied in
correlation with endometriosis pathology is Platelet-derived growth factor.
PDGF is a protein released by platelets that induces proliferation of fibroblasts
(Campbell 2005). The binding of PDGF with its receptor, part of the tyrosine
kinase receptor family, initiates a signal transduction pathway enabling the
connective tissue fibroblasts to divide. It is possible that a combination of all
three of these angiogenic factors is necessary for the development and
maintenance of endometriosis.
5.3 Vascular Endothelial Growth Factor in Endometriosis
In order for endometriosis to progress, endometrial tissue must implant in
an extra-uterine location and obtain a blood supply in order to grow. Active
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endometrial lesions potentially activate angiogenesis within and around adjacent
tissue (Abulafia 1999). Increased levels of angiogenic factors, including VEGF in
the peritoneal fluid of women with endometriosis compared to women without
endometriosis have been observed (McLauren 1996). This finding is consistent
with the endometriosis requirement for angiogenesis and suggests pathology
due to the overexpression of angiogenic factors. It was also observed that VEGF
concentrations were significantly higher during the proliferative phase than the
secretory phase. Taylor et al (1997) showed that increased levels of VEGF and IL8 in peritoneal fluid have positive correlation with the number of active
endometriosis lesions. The same study also demonstrated a fast-acting and direct
effect of E2 on VEGF mRNA and protein synthesis in endometrial stromal cells.
The addition of 10 nM E2 to endometrial stromal cells caused a 50% increase in
VEGF secretion.
As previously mentioned various isoforms of VEGF are responsible for
different functions and properties of angiogenesis. A study by Xu et al (2013)
found increased levels of VEGF-A, VEGF-B, and VEGF-C proteins in the eutopic
and ectopic endometrium of an endometriosis nude mouse model. However,
VEGF-A mRNA in ectopic endometrium and VEGF-C in both eutopic and
ectopic endometrium were found to be significantly higher in patients with
endometriosis than controls. It was also determined that VEGF-C significantly
enhanced development and angiogenesis of endometriosis.
A study by Laschke et al (2007) determined that COX-2 inhibitors inhibit
VEGF-mediated angiogenesis. COX-2 is an enzyme responsible for producing
prostaglandins involved in inflammation, pain, and fever (Lehninger 2008). Two
studies demonstrated that COX-2 inhibition prevents implantation of
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endometrium at ectopic sites, which is a vital step in the survival of endometrial
tissue outside of the uterus, and ultimately development of endometriosis. COX2 inhibitors and their effects will be discussed in more detail in Chapter 10.
5.4 Fibroblast Growth Factor in Endometriosis
FGF-2, as previously mentioned, is an angiogenic growth factor present in
both normal and abnormal endometrium (Bourlev 2006). This factor is important
not only for angiogenesis in general, but also specifically for endometrial
angiogenesis.
FGF-2 induces angiogenesis by binding to one of its receptors FGFR-1 or
FGFR-2 (Möller 2001). Data shows that both receptors of FGF-2 are present in
human endometrium	
  (Ferriani 1993). Specifically, both receptors were expressed
in arteries, but not in veins during the late secretory phase. However, the
expression of FGFR-2 in endometrial glands was observed to be unrelated to
menstrual cycle phase (Möller 2001).
FGF-2 has also been detected in both serum and the peritoneal fluid of
patients with endometriosis	
  (Bourlev 2006). Individuals with surgically
confirmed endometriosis compared with controls had observed higher
concentrations of FGF-2 during both the proliferative and secretory phases of the
menstrual cycle. Also, the FGF-2 levels observed in the peritoneal fluid were
significantly higher than in serum.
5.5 Platelet Derived Growth Factor in Endometriosis
PDGF induces its greatest effects on endometrial luminal and glandular
epithelial cells during the proliferative phase and lesser effects in the secretory
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phase (Chegini 1992). PDGF induces cell division of endometrial stromal cells
suggesting a modulatory role on endometrial cell growth and differentiation.
Surrey et al (1991) used proliferative phase stromal cells isolated from the
endometriotic lesions biopsied from individuals with endometriosis. These cells
grown in culture were used to model the stromal composition of ectopic
endometrium. PDGF and physiological E2 concentrations caused a significant
increase in proliferation of the endometrial stromal cells. This suggests that
PDGF may play an important role in the development or maintenance of
endometriosis.
5.6 Conclusions: A Cooperative Role for VEGF, FGF, and PDGF
Data support cooperation between VEGF, FGF, and PDGF in the ability of
ectopic endometrium to establish and maintain a new blood vessel formation. A
study by Laschke et al (2006) determined that the combined inhibition of VEGF,
fibroblast growth factor, and platelet-derived growth factor effectively
suppressed angiogenesis and vessel maturation of endometrial grafts. The
combined inhibition was more effective than inhibition of VEGF alone.
Combined inhibition significantly reduced the size of the microvascular network
and decreased micro-vessel density. This suggests a cross talk between VEGF,
FGF, and PDGF in the establishment of microvascularization of endometriotic
lesions. Thus, the ability of new endometriotic lesions to develop may strongly
depend on the microenvironment concentrations of these angiogenic factors, and
their inhibition may be one approach to controlling new lesion growth.
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Chapter VI: Immunology of Endometriosis
6.1 Immunology Overview
The immunology of endometriosis has been explored as a potential factor
in the pathology of this disease. Immune cells have been shown to play a critical
role in allowing refluxed endometrial cells to implant and grow rather than be
eliminated. The presence of lymphocytes, natural killer (NK) cells, macrophages,
and mast cells in endometriotic lesions suggests the influence of these immune
cells on this disease. T lymphocytes and macrophages are the two major
leukocyte populations found in endometrial tissue (Osuga 2011). A brief review
of these immune system cells will give a better understanding of their role and
importance as it pertains to endometriosis. This chapter discusses the potential
role of immune cell populations in the pathology of endometriosis.
6.2 Cells of the Immune System
The predominant cells of the immune system are lymphocytes, antigenpresenting cells, and effector cells (Abbas 2012). There are two major types of
lymphocytes that are distinguished based on their functions and how they
recognize foreign substances. B-lymphocytes, the major components of humoral
immunity, account for 20-30% of the circulating lymphocyte population (Ross
2011). These cells are produced in the bone marrow to recognize specific
antigens, differentiate into plasma cells, and synthesize antibodies.
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T lymphocytes, which make up a majority of the circulating lymphocyte
population, characterize cell-mediated immunity (Abbas 2012). These cells
recognize intracellular microbes and either directly induce apoptosis of infected
cells, secrete cytokines, or regulate the immune response. Three different
subpopulations of T lymphocytes serve different functions: T helper cells,
cytotoxic T cells (CTLs), and regulatory T cells (T regs). T cells are educated in
the thymus to recognize and destroy foreign antigens (Ross 2011). The immune
system communicates by sending out signals that lead to activation, recruitment,
or allow for other physiological effects to occur. These signals are typically
released from immune cells as cytokines or chemokines. Secreted cytokines
recruit other cells such as macrophages and neutrophils, which respond by
phagocytosing infected cells.
NK cells, derived from the same precursor cell as T and B cells, are a third
subset of the lymphocyte population that participates in the body’s defense
against viruses and intracellular pathogens (Abbas 2012). These cells are similar
to cytotoxic T cells, but their cell surface receptors are different than those found
on T and B cells.
Macrophages are antigen-presenting cells (APC) of the mononuclear
phagocytic system (MPS), which is a group of cells in which the primary function
is to phagocytose foreign antigens (Abbas 2012). All cells of MPS are derived
from a common precursor cell found in the bone marrow. Two major cell
lineages are derived from a common precursor cell in the bone marrow called
hematopoietic stem cells (HSCs). HSCs can become monocytes, which ultimately
differentiate into macrophages and are activated in multiple tissues in the body.
T helper cells that recognize antigen displayed on the cell surface by antigen
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presenting cells activate macrophages; this causes the T helper cells to release
cytokines that then activate the macrophages (Ross 2011). Macrophages are
recruited to a site of infection by chemokines produced by T cells. T cells also
secrete cytokines that induce other cells to release chemokines for macrophage
recruitment.
A second type of APC is a dendritic cell (DC) (Abbas 2012). DCs play a
crucial role in innate immunity and activation of naïve T cells. These cells are
characterized by long projections, referred to as dendritic processes, of their
membrane. DCs mature in response to a cytokine called Flt3 ligand. They
function by recognizing receptors expressed by microbes, phagocytosing the
foreign pathogen, and presenting the antigen to circulating T cells which are then
activated and can perform its functions.
Mast cells, similar to macrophages in origin, are derived from bonemarrow cells present in mucosal epithelium (Abbas 2012). Mast cells contain
granules in their cytoplasm filled with cytokines and histamine. Mature mast
cells are not typically found in peripheral blood circulation, but are usually
found within tissues near small blood vessels and nerves. Products released by
microbes or via an antibody-dependent mechanism activate mast cells. When
activated these cells release histamine, which is a vasoactive amine that causes
vasodilation and increased capillary permeability. Mast cells also synthesize
prostaglandins and cytokines, such as TNFα Because mast cells are common near
blood vessels and nerves, the release of their contents causes changes in the
blood vessels that lead to acute inflammation. Interleukin 12 (IL-12), a cytokine
involved in CD4+ cell differentiation, is secreted by both macrophages and DCs.
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The binding of this cytokine to its receptor on the surface of NK cells and T cells
induces interferon gamma (IFNγ) synthesis and secretion.
6.3 Immune Cell Involvement in the Menstrual Cycle
Northern et al (1994) conducted a study to determine peripheral
lymphocyte concentrations in normal menstruating women and found that total
white blood cells (WBCs) significantly increased in the blood during the day and
peak around 2 pm on day six of the menstrual cycle. These levels then declined
to their lowest point overnight. Differences were observed in cell counts during
the normal menstrual cycle: white blood cells and B cells were significantly
higher during the proliferative phase, whereas NK cells were significantly higher
during the secretory phase. In general, this study found that daily total WBCs
were lowest in the morning and peaked by 2 pm.
Lee et al (2010) conducted a study to see if the lymphocyte populations in
peripheral blood varied during the menstrual cycle and found that all three
lymphocyte populations fluctuated in response to ovarian phase. T cells were
increased in the follicular phase compared to the luteal phase and NK cell levels
and NK cell toxicity were significantly higher during the luteal phase than the
follicular phase. While B cell concentrations changed during the menstrual cycle,
these changes were not significant.
6.4 Lymphocytes in Endometriosis
Current research suggests that abnormalities in the functions of the
lymphocyte populations could be responsible for the pathology of this disease.
As previously mentioned there are three subsets of the T lymphocyte population:
CTLs, T helper cells, and T regs. Inhibition of the functions of these populations
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has been observed in women with endometriosis as well as in surgically induced
endometriosis animal models. Current research demonstrates that cytotoxic T
lymphocytes that are unresponsive to autologous endometrium are present in
endometriosis. In a study performed by Dmowski et al (1981) the cytotoxicity of
T lymphocytes against autologous endometrium was observed to be significantly
decreased in women with endometriosis. Decreased proliferation of lymphocytes
in response to autologous endometrial cells was seen also in women with
endometriosis (Helvacioglu 1997).
A second method by which endometrial cells have demonstrated an
ability to evade CTL immune surveillance is through cytokine-mediated
expression of the transmembrane protein Fas Ligand (FasL). FasL belongs to the
TNF family and induces apoptosis by binding to its receptor on adjacent cells.
FasL expression by endometrial stromal cells is caused by the cytokine IL-8 and
the chemokine CCL2 (Osuga 2011). Secretion of CCL2 by endometrial cells upregulates FasL mediated apoptosis in T-lymphocytes. This suggested method of
evasion was further supported by two studies by Selam B et al (2002, 2006) that
demonstrated that IL-8 and CCL2 were increased in the serum and peritoneal
fluid of women with endometriosis.
CD4+ and CD8+ T cell abundance or activity is altered in endometriosis.
A few studies have shown a decreased CD4:CD8 ratio in endometriotic
peritoneal fluid (Osuga 2011). CD4+ T helper cells also have decreased activity in
women with endometriosis. While there were high levels of CD4+ T
lymphocytes there were decreased levels of activated CD4+ T lymphocytes
indicating that the activation of these cells has been suppressed in women with
endometriosis. A study by Lee et al (2005) (Lee 2005) showed that THP1 cells,
40	
  

cells of the monocyte cell lineage, exhibited decreased expression of MHC class II
when co-cultured with endometriotic peritoneal fluid. MHC class II is a cell
surface protein that plays a fundamental role in antigen recognition by CD4+ T
cells (Abbas 2012). This protein is crucial in T cell activation and therefore its
decreased expression associated with endometriosis could explain the decreased
cytotoxicity of CD8+ T cells and the decreased activation of CD4+ T helper cells.
Regulatory T cells, a recently discovered subpopulation of T lymphocytes,
are important in suppressing the immune system (Osuga 2011). In women
without endometriosis there is a significantly decreased level of regulatory T
cells in peripheral blood circulation during the secretory phase of the menstrual
cycle, while this was not observed in women with endometriosis. This suggests
that the unsuppressed levels of T regs prevent the recruited immune cell
populations from clearing the shedded endometrial tissue and therefore allow
endometriotic tissue survival and implantation.
The suggested role of B cells in the pathology of endometriosis is via
secretion of autoantibodies. Badawy et al (1989) showed that the amount of IgG
and IgA produced by peritoneal B cells was increased in women with
endometriosis. This suggests an increased B cell activity in endometriosis. A
second study by Odukoya et al (1995) also supports this idea of increased B cell
activity. This lab observed increased serum concentrations of soluble CD23, a
low affinity receptor for IgE that is produced by activated B cells, in patients with
endometriosis.
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6.5 Natural Killer Cells in Endometriosis
Natural Killer (NK) cells are responsible for tumor rejection as well as the
removal of infected cells (Osuga 2011). As previously mentioned NK cells
function by releasing small granules that induce apoptosis. Oosterlynx et al
(1991) showed that in peripheral blood NK cells can destroy endometrial cells,
which suggests the NK cell’s role in clearing refluxed endometrial cells in the
peritoneum. NK cell activity was reduced in women with endometriosis (Viganò
1991 and Garzetti 1993), which suggests that decreased NK cell cytotoxic activity
potentially enables endometriosis development. Also, the reduced function of
NK cell activity was correlated with the severity of endometriosis.
6.6 Macrophages in Endometriosis
Macrophage migration inhibitory factor (MIF), also called Glycosylationinhibiting factor, is a cytokine secreted by macrophages. MIF is an important
immune system regulator and functions in inhibiting macrophage migration
(Abbas 2012). MIF has also been shown to influence angiogenesis and cause
inflammation. Increased levels of MIF were observed in the eutopic endometrial
tissue of women with endometriosis. There were also significantly increased
levels of MIF found in circulation and local peritoneal fluid and in active
endometrial lesions.
A study performed using an MIF inhibitor called (S, R) 3-(4hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic methyl ester (ISO) decreased the
number of endometriotic lesions observed in an in vivo animal model for
endometriosis. The effects of ISO on apoptosis was also examined by looking at
anti-apoptotic and pro-apoptotic factors. Bax, an important pro-apoptotic factor,
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was shown to be upregulated in endometriotic lesions treated with ISO; whereas
there was a significant decrease in protective Bcl2 expression in lesions also
treated with ISO.
6.7 The Role of Inflammatory Cytokines in Endometriosis
Various cells of the immune system secrete inflammatory cytokines such
as TNFα, IL-6, and IL-12. Because endometriosis is characterized by pain
associated with inflammation, the role of pro-inflammatory cytokines in the
development of endometriosis has been examined.
TNFα mRNA expression is increased in the endometrium and peritoneal
fluid of women with endometriosis compared to healthy controls (Kyama 2006).
Kim et al (2013) looked at the effects of both sex steroids and TNFα on a specific
isoform of the Pak family, Pak4. Paks, also called P21-activated kinases, are a
family of serine/threonine kinases that regulate cellular activities, such as
apoptosis, cell motility, proliferation, and steroid receptor signaling (Lodish
2008). Using siRNA-mediated knock down of Pak4 in endometrial glandular and
stromal cells, Pak4 was shown to be responsible for cell motility in invasion
assays. Treatment of endometrial glandular tissue with 10 ng/mL and 25 ng/mL
of TNFα led to a significant increase in Pak4. Also, treatment of endometrial
stromal cells with progesterone led to a significant decrease in Pak4 levels. Pak4
was higher in the eutopic endometrium from patients with endometriosis and
did not vary with menstrual cycle, unlike control patients that had lower Pak4
levels during the secretory phase coincident with higher serum progesterone.
This latter finding is consistent with higher Pak4 levels being associated with the
endometriosis progesterone-resistant phenotype.
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Increased concentrations of IL-6 were also detected in the peritoneal fluid
of women with endometriosis (Bersinger 2012). No fluctuations of these
concentrations were observed throughout the menstrual cycle. IL-12
concentrations were also increased, in endometriosis however, levels were
significantly higher in the secretory phase of the uterine cycle. A summary of the
cytokines mentioned in this section can be found in Table 6.1.
6.8 Conclusions
The role of the immune system in endometriosis pathology, while not
concrete is evident. Immune cell evasion and dysfunction are both linked to the
ability of endometrial cells to implant and develop ectopically. Most cells of the
immune system communicate through chemical signals, causing up and downregulation of other immune system secretions and effects. This suggests a
combined contribution of immune cells and various cytokines to endometriosis
pathology, which makes studies identifying the role of concurrent immune
factors critical.
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Cytokine

Effect

IL-6

Pro-inflammatory
cytokine

IL-12

Pro-inflammatory
cytokine

TNFα

Pro-inflammatory
cytokine and
increases Pak4 levels

Presence in
Endometriosis

Location

Increased in
women with
endometriosis
Increased during
the secretory
phase of the
menstrual cycle
in women with
endometriosis
Increased in
women with
endometriosis

Peritoneal fluid

Bersinger
2012

Peritoneal fluid

Bersinger
2012

Endometrium
and peritoneal
fluid

Kyama 2006
Kim 2013

Table 6.1 Summary of Cytokines involved in Endometriosis
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Chapter VII: Environmental and Dietary Factors
7.1 Overview
Both environmental contaminants and dietary factors have been
postulated to contribute to endometriosis. This chapter discusses current
research that potentially links environmental toxicant exposure and dietary
factors to the development and progression of endometriosis.
Humans are constantly exposed to environmental toxins, particularly
through the diet, which could potentially disrupt physiological processes
possibly causing endometriosis (White 2009 and Bellelis 2011). Environmental
toxins typically remain in the body for long periods of time due to their long
half-life and can over time build up. This accumulation is due in part to the
lipophilic nature of many of the environmental contaminants, which causes them
to associate with and be stored in adipose and lipid rich tissues (White 2009).
Environmental contaminants are being studied as potential endometriosis risk
factors because of their ability to act as endocrine disruptors by altering steroid
synthesis or hormone receptor function, disrupting immune function, and
inhibiting reproductive function by epigenetic modifications (Bruner-Tran 2010).
Dioxins like 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) are
environmental contaminants and have been studied in relation to endometriosis.
TCDD, the structure of which can be seen in figure 1.1, is one of the most well
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studied chemical agents, because of its highly toxic nature (White 2009). In
addition to dietary ingestion of environmental contaminants, other dietary
constituents potentially contribute to endometriosis. Theories regarding dietary
influences on endometriosis include roles for dietary fatty acids, fiber and
phytoestrogens (Parazzini 2013).
7.2 TCDD
TCDD belongs to a family of chlorinated hydrocarbons commonly
referred to as dioxins (White 2009). These fat-soluble toxicants resist degradation
and therefore accumulate in the food supply. This explains why ingestion of
contaminated food is the primary method of exposure.
TCDD typically enters the environment as an industrial by-product or
from incineration (White 2009). TCDD has as estimated half-life of 11.5 years,
which explains the ability of this chemical to easily accumulate in the body upon
consumption of contaminated food. TCDD was first looked at for its potential
role in endometriosis when a primate colony developed a high incidence of this
disease following chronic dietary exposure of TCDD. TCDD levels are typically
high in breast milk (Rier 2002). It has been reported that very high levels of
TCDD are found in the breast milk of Belgium women, which interestingly has
one of the highest endometriosis rates of any country.
Current research has sought to find steroid-mediated endometrial tissue
functions in which exposure to TCDD may alter or inhibit activity (Bruner-Tran
2008). Thus far research supports a link between exposure to TCDD and the
progesterone-resistant endometrial phenotype (Bruner-Tran 2010). As previously
mentioned, retrograde menstruation is the most accepted theory of how
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endometrial tissue makes its way into the peritoneal cavity, but it is the ability of
the endometrial fragments to invade the peritoneal wall that determines the
survival and growth of the endometrial tissue at ectopic sites; TCDD may
influence this event. Metalloproteinases (MMPs) are enzymes needed for tissue
invasion. TCDD in combination with estradiol has been shown to increase MMP
expression and activity by endometrial stromal cells, providing a mechanism for
TCDD promotion of endometriosis (Yu 2008).
TCDD has a high affinity for the aryl hydrocarbon receptor (AhR), which
is an orphan nuclear receptor that is considered to initiate the toxic effects of
these compounds (Bruner-Tran 2008). Unbound AhR receptors, found in the
cytosol, are associated with a complex of chaperone proteins. These receptor
complexes are expressed in both endometrial and immune cells. The binding of
either dioxin or dioxin-like compounds to AhR causes the chaperone proteins to
dissociate and enables the AhR to enter the nucleus. In the nucleus, the AhR
rapidly forms a heterodimeric complex with an aryl hydrocarbon nuclear
translocator (ARNT) protein. This process is shown is Figure 7.1. TCDD
activation of the AhR leads to pro-inflammatory chemokine and cytokine
production (Bellelis 2011). TCDD potentially leads to the development of
endometriosis by inhibiting the anti-inflammatory effects of progesterone. It has
also been shown to function by increasing levels of specific interleukins and by
activating enzymes like aromatase, which would in turn increase estrogen (Rier
2002).
TCDD in combination with estrogen and progesterone has been observed
to induce endometriosis implantation and growth in animals.	
   In a murine model
of endometriosis immunocompromised athymic nude mice were used to implant
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endometrial tissue from normal women and women with endometriosis (BrunerTran 2008). The human tissue exposed to TCDD showed a higher amount of
endoglin staining, a marker for cell proliferation, and exhibited a higher
microvascular density at the peritoneal invasion site than the human tissue
exposed to only estrogen and progesterone. In addition, many neutrophils were
found in the endometrial stroma of the TCDD-exposed tissue. While low levels
of neutrophils present in the lumen of endometrial glands is a normal occurrence
in human endometrium during the secretory phase, increased neutrophil
presence may be related to endometriosis pathology, due to their associations
with early stages of inflammation and their production of the pro-angiogenic
factor VEGF.
TCDD has been shown to cause the progesterone-resistant phenotype seen
in women with endometriosis (Bruner-Tran 2008, 2010). Two isoforms of
progesterone receptor (PR), PR-A and PR-B, are present in endometrial tissue
(Kim 2013). Estrogen typically increases both PRs in normal endometrium. In
endometriotic tissue PR-A levels are lower than eutopic endometrium, and PR-B
is not detectable (Attia 2000). TCDD is suspected of altering the PR isoform
proportions expressed.
PR-B isoform is the primary mediator of anti-inflammatory effects
induced by progesterone (Osteen 2002), however PR-A, which is a truncated
form of the PR, can dominantly suppress PR-B responses (Vegeto 1990). In the
progesterone-resistant phenotype associated with endometriosis patients, high
levels of PR-A expression relative to PR-B are seen in both eutopic and ectopic
endometrial tissue (Attia 2000). Bruner-Tran et al (2010) using a murine model
observed that in utero and prepubertal TCDD exposure causes infertility,
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inability to sustain pregnancy to term, and a significant decrease in PR. This was
observed for several generations of the TCDD-exposed mice indicating, a
possible epigenetic transmission or specific mutations.
Another study produced similar results using adult endometrial stromal
cells (Igarashi 2005). PR-B:PR-A ratios were significantly lower in endometrial
stromal cells in women with endometriosis than in normal endometrial tissue
from control patients. The same study exposed normal endometrial epithelial
and stromal cells to the toxicant TCDD and observed a decrease in PR-B
expression relative to PR-A.
7.3 Dietary Factors
Exposure to environmental toxins via ingestion of contaminated food is
one way that diet potentially influences endometriosis pathology (Bellelis 2011).
Normal dietary constituents themselves may play a role in endometriosis
development or symptoms. Some theories are present regarding dietary
influences, but most correlative data is from individual case reports and reviews
of epidemiological findings do not consistently support any single dietary factor
association with endometriosis (Parazzini 2013). Two topics worth noting are a
potential influence of dietary fatty acids and modulation of estrogen content or
action.
Dietary fatty acids, found in various oils, serve as the substrate for many
prostaglandins including prostaglandin-E2 (PGE2) and prostaglandin-F2alpha
(PGF2α). PGE2 and PGF2α are pro-inflammatory eicosanoids that may increase
uterine contractions and cause pain or dysmenorrhea, a frequent symptom of
endometriosis (Bellelis 2011). Peritoneal explants with endometriotic lesions
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produce higher PGE2 and PGF2α than surrounding normal peritoneum
indicating the lesions were the likely source of the prostaglandins (DeLeon 1988).
Elevated PGE2 in the peritoneal cavity of individuals with endometriosis, was
found to be attributed to both the macrophage population and ectopic
endometrial cells (Sacco 2012). In addition, along with PGE2’s inflammatory
effects, increased VEGF was found in both the peritoneal fluid and lesion
implants of individuals with endometriosis (Li 2005).
PGE2 has also been shown to play a potential role in endometriosisinfertility (Lee 2011). Sperm treated with concentrations of PGE2 similar to those
observed in women with endometriosis showed a decline in fertility caused by
decreased rates of acrosome reaction, which occurs when necessary enzymes for
penetration of the zona pellucida are released by the sperm upon contact with
the egg (Ross 2011); and oocyte penetration.
As mentioned previously, endometriosis is an estrogen-dependent
disease. Altering the level of circulating estrogens can influence endometriosis
pathology. Kaneda et al (1997) demonstrated in women that a diet containing
low fiber showed increased estrogen concentrations and therefore low fiber
intake could potentially be involved in endometriosis risk. Unfortunately, there
is a lack of support for this idea, as data on crude fiber intake and endometriosis
risk do not show a consistent association (Parazzini 2013).
Another way estrogen action and thus endometriosis could be affected by
diet is by the intake of phytoestrogens like those found in soy products.
Soybeans contain isoflavones with estrogen-like properties. Some of these
molecules act as weak estrogen agonists and they may even compete with
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endogenous estrogen for the estrogen receptors thereby lowering the effects of
endogenous estrogens. Two components of soy, genistein and puerarin, have
been investigated using animal models of endometriosis. These soy components
led to a reduction of estrogen concentrations, estrogen receptor levels, and
estrogen production (via aromatase) and in turn reduced size and weight of
endometriotic lesions (Yavuz 2007 and Chen 2011).
7.4 Conclusions
While these environmental toxins and dietary factors have been studied in
relation to endometriosis development, there is not sufficient evidence to
conclude a major role in endometriosis etiology. One reason why the correlation
of chemical toxicant exposure to the ultimate development of endometriosis is
difficult to assess may be that exposure in adults has less of an impact than early
life exposure (Bruner-Tran 2008). It is suggested that toxicant exposure during
fetal life and early development are more relevant to disease advancement due to
the high sensitivity to these disruptors during this critical time in development.
Determining the influence of natural dietary products on endometriosis
development or progression needs long-term case-controlled studies to draw
firm conclusions.
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Figure 7.1 Chemical Structure of TCDD. Reprinted from Chemosphere, Volume
91, Wenxiao Pan, Yuanyuan Qi, Ruoxi Wang, Zhe Han, Dongju Zhang, Jinhua
Zhan, “Adsorption of TCDD with 1-butyl-3-methylimidazolium dicyanamide
ionic liquid: A combined molecular dynamics simulation and quantum
chemistry study,” 157-164, © 2013, with permission from Elsevier.
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Figure 7.2 The Proposed Mechanism of action of the dioxin TCDD. Reprinted
from Environmental Toxicology and Pharmacology, Volume 10, Minghua Nie,
Alan L. Blankenship, John P. Giesy, “Interactions between aryl hydrocarbon
receptor (AhR) and hypoxia signaling pathways,” 17-27, © 2001, with permission
from Elsevier.
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Chapter VIII: Genetic Influence and Polymorphisms
8.1 Overview
Evidence suggests that inheritance patterns and genetic variation play a
potential role in endometriosis pathogenesis (Hoffman 2011). Various mutated
genes that have been passed down are currently being investigated for their role
in this disease. Genetic mutation is responsible for inherited disease in humans
(Lodish 2008). DNA polymorphisms are variations within the DNA sequence
and can be followed throughout generations. Polymorphisms represent normal
variation in a gene’s sequence at a particular site. Unlike mutations, polymorphic
genes are not directly linked to disease, but they can influence an individual’s
predisposition for a disease.
Single nucleotide polymorphisms (SNPs) are the most frequent genetic
variation and are single points in the genomic sequence in which one large
percentage of the population has one nucleotide and another large percentage
has another (Alberts 2002). If two human genomes taken from the world’s
population were sequenced they would differ at approximately 2.5  x  10! points
or about 1 per 1300 nucleotide pairs. Known sites of the human genome in which
there is a high probability that the genomes of two people will differ are referred
to as polymorphic sites. There are two approaches currently used to find
correlations between particular polymorphic genes and endometriosis including
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sibling-pair linkage analysis and gene expression analysis via microarray
technology (Hoffman 2011). This chapter discusses several various
polymorphisms involving genes that regulate inflammation and immune
response, estrogen receptors, and cell cycle regulation. There are many
polymorphism studies that exist to date and new studies are constantly being
published. This chapter will attempt to show a range of polymorphic genes that
have been identified in various populations around the world.
8.2 Specific Polymorphisms and Endometriosis
8.2.1 NFκB
NF-κB is a transcription factor that is important in inflammation and the
immune response (Voet 2011). It is found in the cytosol of cells in an inactive
state when it is bound to an inhibitor IκBα that prevents it from traveling into the
nucleus. However, when pro-inflammatory cytokines such as TNFα and IL-1
bind to cell surface receptors they initiate a signal transduction pathway that
ultimately leads to phosphorylation and dissociation of IκBα. This enables NF-κB
to translocate to the nucleus and activate transcription of its target genes.
An insertion or deletion in the promoter region of the gene encoding the
transcription factor NF-κB functions by decreasing the amount of RNA
transcribed and in turn the amount of protein produced (Bianco 2012). In the
Brazilian population, the insertion of the sequence ATTG causes a decrease in the
production of NF-κB, which is positively correlated with moderate to severe
endometriosis and infertility.
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8.2.2 Estrogen receptors alpha and beta
Because endometriosis is an estrogen-dependent disease, genes that code
for estrogen receptors alpha and beta (ERα and ERβ) are being studied. ERα and
ERβ are similar, but have different mechanisms of action, slight variations in
their gene and protein structures, and are encoded by different genes on separate
chromosomes (Berne 2004). Both estrogen receptors have similar DNA-binding
domains, but the ligand binding domains are only 55% homologous in sequence.
They are also found in different locations. ERα is mostly found in uterine
endometrium, whereas ERβ is typically found in granulosa cells and osteoblasts.
Both receptors have the same affinity for estradiol, but varying affinities for other
forms of estrogen. Estradiol has different actions in various tissues depending on
the presence of a single receptor form or the ratio between the two-receptor
forms.
Several studies examined ERα gene polymorphisms. In a Chinese
population, a dinucleotide TA repeat (genotype E-14 repeats) in the ERα
promoter was associated with endometriosis incidence (Hsieh 2005). In a
Japanese population the PvuII polymorphic locus showed an increased incidence
of the PP genotype with endometriosis (Kitawaki 2001). However, Sato et al
(2008) examined additional intron 1 and exon 1 polymorphisms in the Brazillian
population and concluded that neither of these additional sites correlated with
increased risk of endometriosis in this population.
A study by Silva (2011) looked at the RsaI gene polymorphism in the ERβ
gene. A higher frequency of the heterozygous AG polymorphism was discovered
in individuals with endometriosis compared to patients without endometriosis.
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8.2.3 p53
The transcription factor p53 is a tumor suppressor that oversees genome
integrity (Voet 2011). It plays a critical role in arresting cells that have damaged
DNA and preventing destructive transformation of cells. In response to damage
this factor increases the ability of DNA to activate the transcription of specific
genes that respond to and fix damaged DNA (Lodish 2008).
Two studies examined p53 gene polymorphisms and the association with
endometriosis risk. Ribeiro Júnior et al (2009) studied the Arg72Pro
polymorphism in Brazilian women and found that the proline allele was
significantly associated with intense pain and was more frequent in individuals
with endometriosis. A second study by Govatati et al (2012) did not find an
association between the p53 Arg72Pro polymorphism and endometriosis in
Indian women; however, reduced expression of p53 was found in endometrial
tissue in a small sample (n=5) of women with endometriosis.
Conclusions
The polymorphisms listed above represent only a small sample of those
that have been investigated. No one single polymorphism has been consistently
associated with endometriosis risk across multiple populations. For such studies
to be of value, it is necessary that the normal and endometriosis patient
population that is evaluated be of sufficiently large size, as some prior studies
that have shown associations between a disease and a single nucleotide
polymorphism that have been negated when a larger sample size was included.
Ethnic variations also exist, which can confound data and prevent one from
identifying a single global polymorphism linked to endometriosis risk.
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Figure 8.1 The predicted 3-D structure for Estrogen Receptor-alpha (ER-α)
Kumar, Raj, Mikhail N Zakharov, Shagufta H Khan, Rika Miki, Hyeran Jang,
Gianluca Toraldo, Rajan Singh, Shalender Bhasin, and Ravi Jasuja. 2011. The
dynamic structure of the estrogen receptor. J Amino Acids 2011: 812540.
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Figure 8.2. The predicted 3-D structure for Estrogen Receptor-beta (ER-β)
Kumar, Raj, Mikhail N Zakharov, Shagufta H Khan, Rika Miki, Hyeran Jang,
Gianluca Toraldo, Rajan Singh, Shalender Bhasin, and Ravi Jasuja. 2011. The
dynamic structure of the estrogen receptor. J Amino Acids 2011: 812540.
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Chapter IX: Animal Models
9.1 Overview of Animal Models
Due to the limited ability to perform experimental manipulations in
humans, animal models have been developed in order to study the etiology of
endometriosis. Humans and primates are the only mammals that develop
spontaneous endometriosis and experiments involving primate models are
incredibly expensive, which is why most studies involving primates have a small
sample size. Small animal models using rodents that simulate this disease in
humans have been developed in order to solve this dilemma; however, the
differences between the human menstrual cycle and rodent estrous cycle present
another problem with these studies. While there are limitations to studying this
disease in the current animal models, such models have been useful for studying
in vitro human samples, fetal development, and in vivo effects. This chapter will
discuss the strengths, weaknesses, and findings of these endometriosis animal
models.
9.2 Laboratory Mouse Model
Apparent differences exist between human and murine reproductive
processes, which are necessary to understand when studying the endometriosis
models involving the common laboratory mouse. Instead of a menstrual cycle,
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female mice have an estrous cycle that lasts approximately four to five days. In
order to identify the stage of the estrous cycle in a mouse, it is easy to perform a
vaginal swab and determine the predominance of various vaginal cell types
present at any given time (Caligioni 2009).
The 4-5 day estrous cycle can be divided into four stages: proestrus,
estrus, metestrus, and diestrus respectively. The first stage of the cycle, proestrus,
is characterized by a higher proportion of nucleated epithelial cells and
occasionally keratinized cells in vaginal swabs. During proestrus, there is a thin
layer of stratified squamous epithelium that begins to thicken and some of the
epithelial cells undergo keratinization. This stage is the pre-ovulatory day when
E2 increases, which results in the LH and FSH surge at night, and then ovulation
occurs (Caligioni 2009). Estrus, the second stage of the estrous cycle, is identified
by clusters of irregular shaped keratinized squamous epithelial cells with no
visible nuclei. During estrus the stratified squamous epithelium has thickened
and become fully keratinized. The superficial vaginal epithelial cells begin to
disassociate and move into the lumen. The cytoplasm is observed to be granular
and E2 remains elevated during the morning hours, but falls back to basal levels
by the afternoon.
Metestrus is characterized by low plasma E2 levels and a mix of vaginal
cell types, a majority of them being leukocytes, a few nucleated epithelial and
keratinized squamous epithelial cells. During metestrus regression of the
epithelium also occurs. The leukocytes within the stroma infiltrate the
epithelium. E2 levels begin to rise again in the final stage of the estrous cycle,
diestrus, and the highest percentage of cells in a vaginal lavage smear will be
leukocytes (Conti 2004). The epithelium has thinned and mucified during this
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stage and many of the leukocytes in the stroma migrate into the lumen through
the epithelium.
A considerable physiological difference between mice and humans is that
mice do not menstruate and therefore do not develop spontaneous
endometriosis. This is a limitation of the murine model for endometriosis, but
due to the low cost, the ability to study an in vivo setting, and the capacity to
create knockouts for various genes in mice, the murine model is necessary.
However, endometriosis must be induced in mice either surgically by implanting
human endometrial tissue or by injecting endometrial tissue into the peritoneal
wall (Tirado González 2010). There are two types of murine endometriosis
models, the homologous model and the heterologous model, classified by the
way in which the disease is induced.
The homologous murine model of endometriosis is developed via either
surgical transplantation or by peritoneal injection of endometrial tissue from
another mouse of the same strain (Tirado González 2010). Similar endometrial
models have been achieved in various rodent species such as mice, rats, and
hamsters. The mice receiving the tissue develop endometrioic lesions on the
peritoneal wall, on the intestines, and on the uterine surface. In these animal
models, both the donor and recipient are ovariectomized in order to prevent
hormonal feedback from the ovaries and are given estrogen in order to simulate
the estrous cycle. In the donor mice the exogenous estrogen treatment allows for
the growth and proliferation of viable endometrial tissue for translocation.
However, the estrogen treatment in the recipient mice may influence the
progression of the disease due to its dependence on estrogen. One of the main
problems with this model besides the physiological differences in menstrual and
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estrous cycles is that the endometrial lesions that develop in the murine models
are much smaller and hard to distinguish.
The heterologous model was created using the athymic nude mouse,
which is immunocompromised and therefore can accept xenographs of human
endometrial tissue (Zamah 1984). The nude mouse has a mutation that causes the
failure of thymus development and lack of hair follicles (Abbas 2012). T cell
maturation occurs in the thymus and therefore the nude mouse does not have a T
cell response. In the murine heterozygous model for endometriosis human
endometrial tissue is surgically implanted in the peritoneal wall in order to study
the effects of this tissue. However, the use of this immunocompromised mouse to
study endometriosis pathogenesis is lacking the immune response aspect that
would normally be present and potentially involved in the disease development.
This is a limitation of the heterologous model along with other previously
mentioned restrictions of rodent models.
9.3 Primate Model
Nonhuman primates are the only animals that have a menstrual cycle
similar to humans. Merrill et al (1968) demonstrated that baboons are able to
develop spontaneous endometriosis similar to humans, which is why they have
been used as an animal model. A second study by D’Hoogne et al (1996) further
supported this claim by observing histologically proven spontaneous
endometriosis in a larger group of baboons over a three-year period. This study
consisted of 67 laparoscopies performed on 24 baboons with normal pelvic
cavities. These surgical procedures were done in 3-month intervals over a 32month period. However, a study by Harirchian et al (2012) showed that the
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surgical incisions made during laparoscopies caused endometrial lesions to
develop in their control group; therefore the endometriotic lesions observed in
prior studies (Merrill 1968) may have been caused by the laparoscopies
themselves and not have been a spontaneous occurrence.
The olive baboon, Papio Anubis, is the most commonly used primate
model for endometriosis. It is an important model due to its reproductive
anatomy and menstrual cycle similarity to that seen in women (Stevens 1997).
Endometriosis can be induced in the baboon by endocervical canal resection
(Dehoux 2011) or by injecting autologous endometrial tissue into the peritoneal
cavity (Dhooghe 1997). Induction by endocervical canal resection requires the
removal of part of the cervical canal. The canal is then cauterized in order to
avert menstrual bleeding into the vagina, which simulates retrograde
menstruation. The second method of induction involves removing endometrial
tissue from the uterus of the baboon and then injecting it into the peritoneal
cavity. Both methods of endometriosis induction have been shown to induce this
disease for study. However, studies involving these animals are expensive and
require years for preparation and procedure.
9.4 Importance and Conclusions
The use of non-human primate models of endometriosis provides an
examination of potential factors involved in the development of this disease as
well as dysfunction of the immune response. Due to the physiological
reproductive similarities between non-human primates and humans a greater
understanding of the human pathology of this disease can be discovered.
Problems encountered with the baboon model of endometriosis are the high cost
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and the time needed in order to develop a disease model, which is why rodent
animal models are also necessary.
Even with the limitations of both non-human primate and rodent models
for comparative studies of endometriosis pathology, a lot has been learned about
the factors and physiological disruption involved in the development and
progression of this disease.
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Chapter X: Endometriosis Treatments
10.1 Overview
Many pre-existing drugs have been used to treat endometriosis, however,
because the etiology of this disease remains unknown, there is no cure. Due to
years of research, understanding the involvement of certain factors has provided
a method in which to treat particular symptoms. An important distinction, which
must be made is whether a patient is looking for treatment of pain or infertility,
because the treatment used will be based on the symptoms (Hoffman 2011). In
patients with mild pain, NSAIDs, combination oral contraceptives, and
progestins are used as treatment options; for infertility intrauterine
inseminations in combination with empiric clomiphere is used. Moderate to
severe pain as well as infertility in endometriosis patients can be treated with the
surgical excision, ablation, and lysis of adhesions and further followed by postoperative treatments, such GnRH agonists and aromatase inhibitors, in order to
prevent recurrence. This chapter will examine treatment options for pain and
infertility as well as review the current literature and experimental treatment
options of endometriosis.
10.2 Non-Steroidal Anti-Inflammatory Drugs
Non-steroidal anti-inflammatory drugs (NSAIDs) work by non-selectively
inhibiting cyclooxygenase isoenzymes. These enzymes function in prostaglandin
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synthesis, which is responsible for endometriosis-associated pain and
inflammation (Hoffman 2011). Cyclooxygenase, also referred to as prostaglandin
H! synthase, exists in mammals as two isozymes (COX-1 and COX-2). These
enzymes have different functions, but very similar amino acid sequences. While
COX-1 is responsible for synthesizing the prostaglandins that regulate the
secretion of gastric mucus in the GI tract, COX-2 produces prostaglandins
responsible for inflammation, pain, and fever (Lehninger 2008). Studies designed
to test the effects of decreased prostaglandin synthesis on the symptoms of
endometriosis by inhibiting COX-1, were associated with unpleasant side effects
such as stomach irritation and other serious conditions. After discovery of the
organic structures of COX-1 and COX-2 in the 1990s, NSAID compounds were
created that were specific to COX-2 in order to prevent negative effects of
inhibition of both.
Ota et al (2001) demonstrated that ectopic endometrial tissue expresses
higher levels of COX-2 than eutopic endometrium. Efstathiou et al (2005) using
an in vivo treatment of a murine endometriosis model, found that NSAIDs
produces differential suppression of endometriotic lesion establishment and
growth as compared to controls. Also, Laschke et al (2007) showed that treatment
of a murine model of endometriosis with COX-2 inhibitor showed a 57%
reduction in endometrial lesions compared to controls. In addition, COX-2
inhibitors decreased cell proliferation and VEGF levels, which ultimately
resulted in smaller endometriotic lesions and suppression of angiogenesis.
Although these animal models have shown disease regression with NSAID
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treatment, few studies have critically evaluated the effectiveness of disease
regression in women with surgically confirmed endometriosis (Hoffman 2011).
While there is good evidence for pain relief in women with dysmenorrhea
and pelvic pain using COX-2 inhibitors, the long-term use of these drugs can
cause cardiovascular problems, and should therefore be used in moderation and
for as short a period of time as possible (Nasir 2004). For this reason, other
methods of disease regression are also being studied.
10.3 Combination Oral Contraceptives
Combination oral contraceptives were introduced in the United States
(US) in May 1960 as a method of family planning and pregnancy prevention
(Hatcher 2007). The first oral contraceptive, Enovid, contained 150 µg of
mestranol and 9.85 mg of norethynodrel. These high levels of hormones were
used due to their effectiveness and because studies had not been performed to
identify the lowest effective dose. Today, the concentration of steroid hormones
found in combined oral contraceptives (COCs) has declined dramatically, which
have made these drugs much safer and lessened their side effects. All COCs have
an estrogen and progestin component, which interact with each other. Synthetic
progestins have higher androgenic effects, which can counter some of the
metabolic impact of estrogen on the body; while estrogen can also suppress some
of the progestin effects. These hormone interactions are dependent upon the
concentration of estrogen and progestin in a particular pill.
Two forms of estrogen are used in COCs in the United States, including
mestranol and ethinyl estradiol (EE) (Hatcher 2007). Mestranol is a drug
precursor, which must first be metabolized by the liver into EE before it becomes
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biologically active and effects can take place. Fifty micrograms of mestranol is
equivalent to 35-40 µg of EE, which is more potent and has a longer action time
than the steroid estradiol normally produced by the body. In COCs prescribed in
the US, EE varies from 20 µg to 50 µg per pill. Progestins, the second component
of COCs, are found in eight different forms in the US. Natural progesterone is
not very well absorbed by the GI tract, is readily metabolized, and high doses
cause fatigue. For these reasons, COC developers began looking at long-lasting
compounds (C-19 androgens) to use as the progestin component of the pill rather
than natural forms.
The eight different progestins have made up various COCs and exist
under different “progestin generations” that have developed over time (Hatcher
2007). The first generation of progestins includes norethindrone, norethindrone
acetate, and ethynodiol diacetate. When low dose amounts of progestin are used,
typically norethindrone will be included. The main side effects of the first
generation progestins was spotting and untimely bleeding. In an attempt to
control the side effects of the first generation, the second generation of
progestins, was created. These progestins (norgestrel and levonorgestrel) are
more potent, have incredibly long half-lives, and have more androgenic activity
than the first generation of progestins. A third generation of progestins
(desogestrel and norgestimate) was created to exert a lower androgenic activity
than the second generation and to main an increased progestational activity. The
decreased androgenic activity of these third generation progestins allowed for a
fuller metabolic effect of the COCs estrogen component.
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There are two formulations of COCs available: monophasic and
multiphasic. Monophasic contraceptive indicates that each active pill is
composed of the same doses of the estrogen and progestin as the other active
pills; whereas multiphasic signifies that the amounts of hormones in the active
pills vary (Hatcher 2007). Traditionally, monophasic COCs are prescribed for the
treatment of endometriosis, but no studies offer proof in support of their clinical
superiority to multiphasic COCs (Hoffman 2011).
The mechanism of action of COCs includes reducing menstrual flow and
potentially the volume of retrograde menses, decreasing GnRH pulses and
pituitary responsiveness to GnRH stimulation, suppression of LH and FSH
synthesis, and in some cases suppressing the mid-cycle LH surge (Maia 2008). By
suppressing the hormones required for ovulation, ovarian estradiol production
decreases, removing the stimulus for endometriotic implants and reducing the
risk of developing endometriotic lesions. COCs also work by causing the pseudodecidualization of these endometriotic lesions. Pseudo-decidualization is caused
by progestin induction of terminal differentiation of endometrial cells, which
stops their growth. The progestin component of COCs, therefore results in
reduced symptoms of endometriosis during use. However, this treatment does
not cure the disease, because lesions only stop growth during treatment and are
ready for re-growth when COC use is discontinued (Hatcher 2007).
10.4 Surgical Treatment of Endometriosis
The principle manner in which endometriosis diagnosis is confirmed is
via laparoscopy; for this reason, surgical treatment of the disease at the time of
diagnosis seems appropriate (Hoffman 2011). Surgery can be used to treat either
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symptom of endometriosis—moderate to severe pain or infertility. The benefits
of surgery for individuals with severe forms of this disease include a mended
pelvic anatomy, excision of implanted endometriotic lesions, and ultimately
decreased inflammation (Macer 2012). There are two methods of endometriotic
lesion removal: excision or ablation. Excision involves the complete removal of
the lesion and ablation entails the destruction of ectopic endometrial tissue with
conventional electrosurgery or a high-energy laser.
According to a study by Blackwell et al (1991) laser ablation does not
prove to be more effective than electrosurgery. However, regarding laparoscopic
ablation versus the excision of endometriomas, excision was associated with a
subsequent increased spontaneous pregnancy rate in women who were
documented as infertile. A randomized controlled study consisting of 341
women was conducted in order to discover whether laparoscopic surgery
increased the fertility rate of endometriosis-associated infertility. It was
concluded that ablation of endometriotic lesions significantly enhanced the
fertility of women compared with diagnostic laparoscopy alone (Macer 2012).
Vercellini et al (2013) compared surgical treatment of endometriosis
(ablation via electrosurgery) to a low-dose progestin treatment for diseaseassociated deep dyspareunia in 192 women diagnosed with stage III and IV
endometriosis. This study compared the Female Sexual Function Index (FSFI), a
19-item questionnaire that evaluates the major groups of female sexual
dysfunction and sexual satisfaction, of individuals undergoing surgery to those
taking a progestin treatment. Patients that received surgery observed a
substantial and rapid benefit (increased FSFI score) compared to the progestin
treatment group. However, over the course of the study, performance of the
72	
  

surgery group on the FSFI deteriorated and no significant difference was
observed between the two groups in the long term.
These studies indicate an initial suppression of symptoms after ectopic
endometrial implants are removed, but suggest a recurrence of symptoms
potentially due to regrowth of endometriotic lesions months after the initial
excision. Also, the surgery itself can potentially cause other lesions to grow
(Harirchian 2012), which also may be responsible for the return of endometriosisassociated pain. Typically post-operative treatments for both pain and infertility
are necessary for successful liberation from symptoms. However, even with a
combination of surgery and post-operative treatments, a percentage of patients
have a recurrence of symptoms.
10.5 Post-operative Treatments
In two studies of 95 participants a statistically significant reduction in the
recurrence of dysmenorrhea was observed in a group that received postoperative treatment than in the control group that only had surgery (AbouSetta
2013). The post-operative treatment in this review was a levonorgestrel-releasing
intrauterine device (IUD). As previously mentioned levonorgestrel is a potent
progestin that decreases the metabolic activity of estrogen. This treatment
suppresses the effects of estrogen and has a similar mechanism of action to the
other post-operative treatments that are used.
GnRH causes the release of the gonadotropin hormones and subsequent
ovarian steroidogenesis and ovulation. However, continuous, nonpulsatile
GnRH administration causes the anterior pituitary to become desensitized and
decrease ovarian steroidogenesis (Hoffman 2011). This result allows GnRH

73	
  

agonists to be used to treat endometriosis. Ultimately, GnRH agonists cause loss
of estradiol production, which is necessary for the implantation and
development of endometriotic lesions. This post-operative treatment allows for a
pseudo-menopausal state and allows the body to recover, while simultaneously
suppressing the disease from reforming.
The third class of post-operative treatments, aromatase inhibitors, works
by a mechanism similar to that of its counterparts. As previously mentioned
aromatase is an enzyme that catalyzes the conversion of testosterone to estrogen;
therefore aromatase inhibitors would decrease the amount of estrogen produced
by the ovaries. In one study, aromatase inhibitors were used for the treatment of
severe menopausal endometriosis (Takayama 1998). This treatment was given
after a woman underwent a complete hysterectomy and a bilateral salpingooophorectomy, in which both of the woman’s ovaries and fallopian tubes were
removed. This individual experienced significant pain relief and reduction of
lesion size after nine months. A second study, involving a baboon model for
endometriosis, showed a significant reduction in endometrial ectopic lesion size
when treated with aromatase inhibitors, whereas the control group given a
placebo experienced endometrial lesion growth (Langoi 2012). These postoperative treatments have shown to be necessary in successful suppression of
this disease. These studies reconfirm the role of estrogen in endometriosis
sustenance.
	
  

74	
  

Chapter XI: Conclusion
Many factors play a role in the development and pathology of
endometriosis, which explains why the etiology of this disease remains elusive.
Current research supports the theory of retrograde menstruation along with the
dysfunction of the immune response to misplaced endometrial tissue and
increased secretion of angiogenic factors by ectopic endometrium. Other such
factors that potentially increase endometriosis-associated inflammatory
responses are environmental toxicants and inherited genetic variation, otherwise
known as single-nucleotide polymorphisms, which alter various genes that are
potentially involved in endometriosis pathogenesis.
The only method to absolutely diagnose endometriosis is by surgical
laparoscopy. Because it has been discovered that surgery alone can induce
endometrial lesion formation, alternative modes of diagnosing endometriosis,
such as by ultrasound, should be a developed. The current classification system
of endometriosis by the American Fertility Society does not provide information
on the severity of pain or fecundity. The Endometriosis Fertility Index attempts
to bridge this gap, however, it is not currently a widely accepted method of
identifying fertility in endometriosis patients. In order for preventative measures
to be taken an endometriosis-associated pain predictor is needed.
Animal models, even with their limitations, have brought us steps
closer to understanding steroid responses, angiogenic and immunologic factors
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produced in vivo, and the role of certain genes using knock-out mice. However,
a higher level of understanding may not be obtained without more clinical trials.
Treatments exist to aid in suppressing the symptoms of endometriosis, but due
to the elusive nature of the disease, there is no cure. Endometriosis is a complex,
multi-factorial disease; and while we’ve gained valuable knowledge on the
potential factors involved, further research is necessary to achieve a better
understanding of the pathogenesis of this disease. 	
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